A5046022513- Transplantation: Methods and Outcomes
- Respiratory viral infections research
- Polyomavirus and related diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Organ Transplantation Techniques and Outcomes
- Tracheal and airway disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- SARS-CoV-2 and COVID-19 Research
- Esophageal and GI Pathology
- Organ and Tissue Transplantation Research
- Telomeres, Telomerase, and Senescence
- Cardiac Structural Anomalies and Repair
- Viral-associated cancers and disorders
- Vasculitis and related conditions
- Multiple Myeloma Research and Treatments
- COVID-19 Impact on Reproduction
- Oral health in cancer treatment
- Venous Thromboembolism Diagnosis and Management
- Medical Imaging and Pathology Studies
- Antifungal resistance and susceptibility
- Pneumocystis jirovecii pneumonia detection and treatment
- Teratomas and Epidermoid Cysts
- Hepatitis C virus research
Brigham and Women's Hospital
2019-2024
Harvard University
2020-2024
Boston Medical Center
2024
VA Boston Healthcare System
2023
Veterans Health Administration
2022
Duke Medical Center
2018
Emory University
2015
Background. Respiratory syncytial virus (RSV) infection in lung transplant recipients (LTRs) causes mortality rates of 10%–20% despite antiviral therapy. Ribavirin (RBV) has been used to treat RSV-infected LTRs with limited data. Methods. A retrospective study including all at Duke Hospital during January 2013–May 2017 positive RSV polymerase chain reaction respiratory specimens was performed. Results. Fifty-six 70 patients the oral RBV group and 29 32 inhaled had symptomatic infection. One...
Background: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases risk complications in patients with idiopathic pulmonary fibrosis. Objectives: To investigate between discontinuation and fibrosis affects complications. Methods: We assessed intra-operative post-transplant among who underwent had been treated nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to they a shorter (⩽ 5 medication...
Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is form of advanced immunosuppression currently used as therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in transplant recipients.Side effects alemtuzumab include bone marrow suppression, infection malignancy. Whether can be safely recipients have an increased propensity suppression due to telomeropathies unknown.In retrospective case series, we report outcomes associated...
Non-HLA antibodies against heterogeneous targets on endothelial cells have been associated with allograft injuries. The cell crossmatch (ECXM) is used in the detection of non-HLA but remains non-discriminatory for specific antibody identification. primary objective this study was to delineate signatures ECXM positivity and determine correlation status health. Serum specimens from 25 lung transplant recipients (LTRs) 13 renal (RTRs) were collected as part clinical evaluation, testing...
Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have been associated with bronchiolitis obliterans syndrome (BOS). However, limited data exists regarding the association of RSV other types rejection. This retrospective study all RSV-infected LTRs at Duke University from January 2013 to May 2017 examined acute cellular rejection (ACR), antibody mediated (AMR), new human leukocyte antigen (HLA) detection, donor-specific (DSA) BOS development and progression 1...
Abstract Background Epstein-Barr virus (EBV) donor seropositive/recipient seronegative (D+/R-) status is a risk factor for post-transplant lymphoproliferative disorder (PTLD) which associated with increased mortality post-lung transplant. The optimal surveillance strategy PTLD transplant stratified by EBV serostatus early diagnosis unknown. We assessed serial viral loads (VL) of and compared outcomes in D+/R- R+ lung recipients at our center. Methods A single-center retrospective study...
Abstract Background Invasive fungal disease (IFD) is common after lung transplant and associated with increased morbidity mortality. Antifungal prophylaxis a preventative strategy against IFD in recipients (LTRs). We assessed the incidence of first 3-years post-transplant, diagnosed by EORTC/MSG criteria, risk factors for developing IFD, outcomes LTRs stratified development at single center that does not use universal antifungal post-lung transplant. Table 1 Preoperative perioperative...
Respiratory syncytial virus (RSV) is a common community acquired infection in lung transplant recipients (LTRs). The mortality RSV-infected LTRs has been reported as 10–20% despite antiviral therapy; however, there no consensus regarding treatment given limited data. A retrospective study of all at Duke University during January 2013 and May 2017 with positive RSV PCR respiratory specimen was performed. Baseline characteristics, sites infection, therapy, side effects, outcomes including...
Abstract Background Staphylococcus aureus (S. aureus) infections post-lung transplant lead to increased mortality. The impact of S. peri-transplant respiratory cultures on post-transplant outcomes is unknown as the optimal duration antibiotics. We compared lung recipients with and without growth 6-month including rejection, survival, occurrence infections. Methods A single-center, retrospective study between January 2017 April 2021 was performed. Donor/recipient characteristics,...
Advanced hepatic fibrosis and cirrhosis are absolute contraindications to lung transplantation. [ 1] However, whether fatty liver disease with mild–moderate contributes increased adverse outcomes post-lung transplantation remains unknown. We present a retrospective analysis of patients transplanted at Brigham Women's Hospital between 2015 2017 identify non-alcoholic (NAFLD) experience short-term complications compared normal architecture. Patients advanced (F3–F4) and/or were considered...